How to Buy Humacyte Stock
Humacyte Inc
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Humacyte stock last closed at $1.62, down 4.14% from the previous day, and has decreased 68.54% in one year. It has underperformed other stocks in the Biotechnology industry by 0.45 percentage points. Humacyte stock is currently +40.87% from its 52-week low of $1.15, and -76.07% from its 52-week high of $6.77.
There are currently 158.37M shares of HUMA outstanding. The market cap of HUMA is $256.56M. In the past 24 hours, 3.65M HUMA shares were traded.
How to Buy Humacyte Stock
Not sure how to invest in Humacyte stock? Here's how.
- Decide where to buy Humacyte stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Humacyte stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Research Humacyte stock: The Humacyte ticker symbol is HUMA. Is Humacyte stock a good investment? Should you buy shares of HUMA? How do HUMA's underlying business fundamentals look? Do top analysts think Humacyte is a good buy? Why has HUMA's stock price moved recently? (Hint: Our stock market research website can help you figure out if HUMA is a good stock to buy).
- Make your HUMA trade: Decide if you will purchase HUMA shares at the current market price or use a limit order to purchase HUMA shares at a given price.
- Get key alerts regarding your investment in HUMA: Create a watchlist to keep tabs on your new investment in Humacyte stock.
Step 1: Decide where to buy Humacyte stock
You need a brokerage account in order to access the NASDAQ market and buy HUMA shares.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can buy HUMA today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have created your account on the highest rated app to buy and sell stocks, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring money into your new investment account.
Step 4: Research Humacyte stock
Once you have decided on the best place to buy Humacyte stock, it's important to analyze their stock prior to buying, so you actually understand the risk and opportunity.
Humacyte Metrics
Humacyte Due Diligence Score
WallStreetZen was designed to help everyday investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on HUMA's stock page.
How is HUMA stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge HUMA's fair value.
Using relative valuations ratios:
- HUMA could be overvalued based on its P/B ratio of 63.32x, relative to Biotechnology industry P/B ratio of 4.97x
You can do additional valuation research on HUMA's stock here.
A quick look at HUMA Financials
Signs that HUMA is financially healthy:
- There are more short-term assets than short-term liabilities on the HUMA balance sheet.
Signs that HUMA is not financially healthy:
- HUMA has a relatively high debt to equity ratio of 33.25.
- HUMA has $88.24M in cash and short term investments. This is not sufficient to cover its annual cash burn of $106.29M.
- There are more long-term liabilities than short-term assets on the HUMA balance sheet.
- HUMA profit margin has gone down from N/A to -7,171.3% in the past year.
- HUMA has cash burn of 106291000. It does not have sufficient cash and short-term investments to cover this.
Is it a good time to buy Humacyte stock, according to analysts?
Out of 6 Equities analysts who give recommendations on HUMA, the consensus analyst rating on Humacyte is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent HUMA Analyst Forecasts
Bruce Jackson, a bottom 1% analyst from Benchmark maintains HUMA with a strong buy rating and lowers their HUMA price target from $17.00 to $14.00, on May 14, 2025.
You can dive deeper into what analysts are forecasting on the Humacyte stock forecast page.
HUMA Technicals
Is HUMA Making Money?
Last year, HUMA revenue was $818.00k. Over the last four year, HUMA's revenue has increased by -18.82% per year. This was slower than the Biotechnology industry average of 70.04%.
Dig into HUMA's earnings and revenue performance here.
Are HUMA executives and large shareholders buying or selling the stock?
In the last year, insiders at HUMA have sold more shares than they have bought.
Brady W. Dougan, Director of HUMA, was the latest HUMA insider to sell. They sold $934,862.30 worth of HUMA shares on Aug 20, 2025.
Learn more about who owns HUMA stock here.
Does HUMA provide a stable income stream?
No, Humacyte doesn't provide an income stream by paying out dividends.
HUMA Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your HUMA trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, use a limit order.
Click the Open button and eToro will place your order.
If you need more info about buying stocks on eToro, click the how to video below:
Step 6: Get key alerts regarding your investment in HUMA
Now that you own some shares in HUMA, you'll want to stay up-to-date on your new shares.
Add HUMA to a watchlist to monitor your HUMA stock.
HUMA Feed
How to Buy Stock in Humacyte
To summarize, here are the 6 steps you need to take to buy Humacyte stock right now:
- Decide where to buy Humacyte stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Humacyte stock
- Make your HUMA trade
- Get key alerts regarding your investment in HUMA
If you require a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep an eye on your new investment in Humacyte, click the button below.
More Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.